Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib +/- Pembrolizumab in Pancreatic Cancer
NCT02362048Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- May 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Acerta Pharma. Started May 2015; status: completed.
02
Drugs
acalabrutinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02362048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362048.